NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TLPH

Talphera Inc

Jun 30 • 04:00PM ET

0.4602

Dollar change -0.0078
Percentage change -1.67	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: LLY PFE MRK BMY JNJ GILD REGN AMGN VRTX BIIB

| Held by: VXF VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	4.00%	Shs Outstand	20.50M	Perf Week	4.59%
Market Cap	9.44M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	36.41%	Shs Float	19.68M	Perf Month	-6.10%
Enterprise Value	10.58M	PEG	-	EPS next Q	-0.12	Inst Own	31.31%	Short Float	1.08%	Perf Quarter	-21.47%
Income	-11.64M	P/S	314.67	EPS this Y	-2.00%	Inst Trans	48.44%	Short Ratio	4.53	Perf Half Y	-25.57%
Sales	0.03M	P/B	1.41	EPS next Y	-23.53%	ROA	-53.54%	Short Interest	0.21M	Perf YTD	-12.19%
Book/sh	0.33	P/C	1.75	EPS next 5Y	17.57%	ROE	-106.83%	52W High	1.19 -61.33%	Perf Year	-47.70%
Cash/sh	0.26	P/FCF	-	EPS past 3/5Y	55.88% 48.17%	ROIC	-96.02%	52W Low	0.43 7.02%	Perf 3Y	-88.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	0.00%	Volatility	7.54% 7.48%	Perf 5Y	-98.31%
Dividend TTM	-	EV/Sales	352.67	EPS Y/Y TTM	49.94%	Oper. Margin	-51596.30%	ATR (14)	0.03	Perf 10Y	-99.43%
Dividend Ex-Date	-	Quick Ratio	3.11	Sales Y/Y TTM	-95.85%	Profit Margin	-43122.22%	RSI (14)	43.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.11	EPS Q/Q	38.27%	SMA20	-3.72%	Beta	-0.11	Target Price	4.17
Payout	-	Debt/Eq	1.17	Sales Q/Q	-	SMA50	-6.90%	Rel Volume	0.99	Prev Close	0.47
Employees	13	LT Debt/Eq	1.17	Earnings	May 14 AMC	SMA200	-29.05%	Avg Volume	46.90K	Price	0.46
IPO	Feb 11, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.22% -	Trades		Volume	46,244	Change	-1.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$4
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral	$7 → $2
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy	$6.50
Feb-15-19	Initiated	Credit Suisse	Outperform	$7
Oct-23-18	Initiated	B. Riley FBR	Buy	$9
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform	$6 → $5
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Jul-14-17	Resumed	Jefferies	Buy	$7
Sep-15-16	Reiterated	ROTH Capital	Buy	$11.25 → $15
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy	$8.50 → $10.50
Sep-02-15	Initiated	H.C. Wainwright	Buy	$8.50
Jul-10-15	Resumed	ROTH Capital	Buy	$7.50
May-06-15	Reiterated	Mizuho	Neutral	$5.50 → $3
May-05-15	Reiterated	RBC Capital Mkts	Outperform	$8 → $7
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform	$12 → $8

Show Previous Ratings

May-15-25 03:16AM	Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... (GuruFocus.com)
May-14-25 04:05PM	Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-07-25 04:05PM	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 (PR Newswire) +6.97%
May-06-25 12:00PM	All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy (Zacks)
Apr-04-25 12:00PM	Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.35%
03:03AM	Loading…
Apr-01-25 03:03AM	Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights (GuruFocus.com) +7.07%
Mar-31-25 06:33PM	Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript (Seeking Alpha) -15.53%
04:05PM	Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million (PR Newswire)
Mar-26-25 04:38PM	Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 (PR Newswire)
Jan-14-25 08:30AM	Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study (PR Newswire)
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-14-24 02:14AM	Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com) -25.61%
Nov-13-24 04:05PM	Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-24 04:05PM	Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 (PR Newswire)
04:54PM	Loading…
Oct-08-24 04:54PM	Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Sep-05-24 04:15PM	Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +5.62%
Aug-19-24 08:30AM	Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit (PR Newswire)
Aug-14-24 04:01PM	Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -5.49%
Aug-05-24 04:05PM	Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 (PR Newswire)
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +6.02%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +5.88%
May-20-24 05:25PM	Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-16-24 05:45PM	Talphera to Participate at A.G.P. Virtual Healthcare Conference (PR Newswire) -5.35% -6.09%
May-14-24 08:56PM	TLPH Stock Earnings: Talphera Beats EPS for Q1 2024 (InvestorPlace) +19.12%
04:05PM	Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-02-24 04:15PM	Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 (PR Newswire)
Mar-06-24 09:53PM	TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.63%
04:05PM	Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-24 07:30AM	Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members (PR Newswire)
04:15PM	Loading…
Feb-26-24 04:15PM	Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 (PR Newswire)
Jan-18-24 08:30AM	Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering (PR Newswire) +26.01%
Jan-09-24 09:05AM	AcelRx Announces Rebranding With Name Change to Talphera, Inc. (PR Newswire) +7.50%
Dec-12-23 08:30AM	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States (PR Newswire) -9.01%
Nov-09-23 11:06AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.34%
Nov-08-23 05:22PM	AcelRx Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 04:05PM	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study (PR Newswire)
Oct-26-23 04:30PM	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 (PR Newswire)
Oct-03-23 08:30AM	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study (PR Newswire)
Sep-12-23 01:02PM	Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc (GuruFocus.com) +12.80%
Sep-06-23 08:30AM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire)
Aug-22-23 05:30PM	What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks)
Aug-13-23 05:33AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:07AM	Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.46%
04:20PM	AcelRx Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-23 04:05PM	AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 (PR Newswire)
Jul-21-23 08:00AM	AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jul-18-23 08:00AM	AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (PR Newswire)
May-10-23 06:25PM	AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1 (Zacks) +10.88%
05:18PM	AcelRx Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:05PM	AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-04-23 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-27-23 04:05PM	AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 (PR Newswire)
Apr-05-23 08:30AM	AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire)
Apr-04-23 12:30PM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.00%
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 (PR Newswire) +18.10% +5.68%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire) -21.05%
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures (PR Newswire) -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside (Insider Monkey) -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine (PR Newswire)
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +17.96%
04:01PM	AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 08:30AM	AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 (PR Newswire)
Oct-31-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 (PR Newswire)
Oct-27-22 08:30AM	AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant (PR Newswire) -12.47%
Oct-26-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 (PR Newswire) -12.81%
Oct-25-22 04:42PM	AcelRx Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences (PR Newswire)
Sep-06-22 04:30PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire) -7.32% +5.74%
Aug-25-22 08:30AM	AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Aug-11-22 05:35PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +33.02% -13.63%
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 (PR Newswire)
Aug-10-22 08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Jul-28-22 04:50PM	AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 (PR Newswire)
Jul-08-22 06:28AM	AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years (Simply Wall St.) -13.71%
May-20-22 12:49PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference (PR Newswire) -11.83%
May-19-22 11:56AM	Why AcelRx Pharma Shares Are Trading Higher Today? (Benzinga) +27.63%
08:30AM	AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® (PR Newswire)
May-16-22 08:45AM	AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-12-22 05:35PM	Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +17.66%
May-10-22 05:35PM	Organogenesis (ORGO) Q1 Earnings Lag Estimates (Zacks) -10.10%
08:30AM	AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia (PR Newswire)
May-09-22 07:30PM	AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 (PR Newswire) -13.47%
Apr-27-22 08:00AM	AcelRx Hosting Key Opinion Leader Webinar on Niyad Nafamostat Program (GlobeNewswire)
Apr-25-22 08:30AM	Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 (PR Newswire)
Apr-21-22 08:30AM	AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 (PR Newswire) -8.00%
Mar-31-22 04:10PM	AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures (PR Newswire)
Mar-29-22 01:08PM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit (PR Newswire) -6.87%

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Apr 02 '25	Buy	0.59	213,310	125,000	403,769	Apr 03 04:28 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Dec 05 '24	Buy	0.64	5,000	3,200	208,066	Dec 06 06:05 AM
ASADORIAN RAFFI	Chief Financial Officer	Dec 02 '24	Sale	0.77	155	119	37,578	Dec 02 04:22 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Nov 27 '24	Buy	0.73	5,000	3,650	203,066	Dec 02 04:20 PM
ASADORIAN RAFFI	Officer	Dec 02 '24	Proposed Sale	0.69	155	107		Dec 02 12:31 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Aug 30 '24	Buy	1.05	7,260	7,598	198,066	Sep 03 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLPH

Talphera Inc

Upgrade your FINVIZ experience